Brooklyn ImmunoTherapeutics Stock Forecast, Price & News

-0.03 (-0.28 %)
(As of 07/27/2021 05:09 PM ET)
Today's Range
50-Day Range N/A
52-Week Range
Volume508,228 shs
Average Volume6.76 million shs
Market Capitalization$452.03 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Brooklyn ImmunoTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Brooklyn ImmunoTherapeutics logo

About Brooklyn ImmunoTherapeutics

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.68 out of 5 stars

Medical Sector

1642nd out of 2,218 stocks

Biotechnology Industry

40th out of 94 stocks

Analyst Opinion: 0.0Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Brooklyn ImmunoTherapeutics (NYSEAMERICAN:BTX) Frequently Asked Questions

What stocks does MarketBeat like better than Brooklyn ImmunoTherapeutics?

Wall Street analysts have given Brooklyn ImmunoTherapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Brooklyn ImmunoTherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Brooklyn ImmunoTherapeutics' next earnings date?

Brooklyn ImmunoTherapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Brooklyn ImmunoTherapeutics

How were Brooklyn ImmunoTherapeutics' earnings last quarter?

Brooklyn ImmunoTherapeutics, Inc. (NYSEAMERICAN:BTX) posted its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.06. The biotechnology company had revenue of $1.27 million for the quarter, compared to analyst estimates of $1.75 million.
View Brooklyn ImmunoTherapeutics' earnings history

Who are Brooklyn ImmunoTherapeutics' key executives?

Brooklyn ImmunoTherapeutics' management team includes the following people:
  • Dr. Howard J. Federoff M.D., Ph.D., CEO, Pres & Director
  • Dr. Monil Shah M.B.A., Pharm.D., Chief Operating Officer
  • Dr. Kevin A. D'Amour, Chief Scientific Officer
  • Mr. Ronald Guido M.S., Chief Devel. Officer (Age 64)
  • Ms. Lynn Sadowski Mason M.S., Exec. VP of Clinical Operations
  • Mr. Stephen R. Goldberg, Sec.

Who are some of Brooklyn ImmunoTherapeutics' key competitors?

What other stocks do shareholders of Brooklyn ImmunoTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Brooklyn ImmunoTherapeutics investors own include CA (CA), Asterias Biotherapeutics (AST), Geron (GERN), Micron Technology (MU), BlackRock (BLK), Endologix (ELGX), OPKO Health (OPK), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP) and Chipotle Mexican Grill (CMG).

What is Brooklyn ImmunoTherapeutics' stock symbol?

Brooklyn ImmunoTherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."

How do I buy shares of Brooklyn ImmunoTherapeutics?

Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Brooklyn ImmunoTherapeutics' stock price today?

One share of BTX stock can currently be purchased for approximately $10.59.

How much money does Brooklyn ImmunoTherapeutics make?

Brooklyn ImmunoTherapeutics has a market capitalization of $452.03 million.

How many employees does Brooklyn ImmunoTherapeutics have?

Brooklyn ImmunoTherapeutics employs 10 workers across the globe.

What is Brooklyn ImmunoTherapeutics' official website?

The official website for Brooklyn ImmunoTherapeutics is www.biotimeinc.com.

Where are Brooklyn ImmunoTherapeutics' headquarters?

Brooklyn ImmunoTherapeutics is headquartered at 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States.

How can I contact Brooklyn ImmunoTherapeutics?

Brooklyn ImmunoTherapeutics' mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390.

This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.